Fludarabine-Melphalan Conditioning for AML and MDS: Alemtuzumab Reduces Acute and Chronic GVHD without Affecting Long-Term Outcomes Koen Van Besien, Rangesh Kunavakkam, Gaby Rondon, Marcos De Lima, Andrew Artz, Betul Oran, Sergio Giralt Biology of Blood and Marrow Transplantation Volume 15, Issue 5, Pages 610-617 (May 2009) DOI: 10.1016/j.bbmt.2009.01.021 Copyright © 2009 American Society for Blood and Marrow Transplantation Terms and Conditions
Figure 1 Survival. Biology of Blood and Marrow Transplantation 2009 15, 610-617DOI: (10.1016/j.bbmt.2009.01.021) Copyright © 2009 American Society for Blood and Marrow Transplantation Terms and Conditions
Figure 2 Progression-Free Survival. Biology of Blood and Marrow Transplantation 2009 15, 610-617DOI: (10.1016/j.bbmt.2009.01.021) Copyright © 2009 American Society for Blood and Marrow Transplantation Terms and Conditions
Figure 3 Acute GVHD. Biology of Blood and Marrow Transplantation 2009 15, 610-617DOI: (10.1016/j.bbmt.2009.01.021) Copyright © 2009 American Society for Blood and Marrow Transplantation Terms and Conditions
Figure 4 Chronic GVHD. Biology of Blood and Marrow Transplantation 2009 15, 610-617DOI: (10.1016/j.bbmt.2009.01.021) Copyright © 2009 American Society for Blood and Marrow Transplantation Terms and Conditions
Figure 5 Cumulative Probability of Treatment-Related Mortality. Biology of Blood and Marrow Transplantation 2009 15, 610-617DOI: (10.1016/j.bbmt.2009.01.021) Copyright © 2009 American Society for Blood and Marrow Transplantation Terms and Conditions
Figure 6 Cumulative probability of Disease Recurrence. Biology of Blood and Marrow Transplantation 2009 15, 610-617DOI: (10.1016/j.bbmt.2009.01.021) Copyright © 2009 American Society for Blood and Marrow Transplantation Terms and Conditions